Monday, October 23, 2017 7:01:55 PM
October 18, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported that patient enrollment is now complete in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF). The 100-patient study, known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study, is sponsored by Duke Clinical Research Institute (DCRI) as the Coordinating Center for the Heart Failure Clinical Research Network (HFN) and is being conducted at various clinical centers that are part of the HFN. Savara expects that top-line results from the INDIE-HFpEF study will be available in the first half of 2018.
Recent SVRA News
- Savara to Host Analyst and Investor Webinar on September 30, 2024 • Business Wire • 09/23/2024 12:05:00 PM
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 09/08/2024 10:45:00 AM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/06/2024 08:05:00 PM
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/03/2024 08:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 08/16/2024 08:05:00 PM
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 08/15/2024 12:05:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 12:45:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:21 PM
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/12/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/26/2024 08:09:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 08:16:53 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/08/2024 08:32:40 PM
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock • Business Wire • 06/28/2024 12:50:00 PM
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 06/26/2024 10:30:00 AM
- Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 06/26/2024 12:05:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/10/2024 09:07:03 PM
- Savara to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/22/2024 04:15:18 AM
- Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 • Business Wire • 05/19/2024 04:15:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 05/16/2024 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 08:46:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:10:48 PM
- Savara Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/09/2024 08:05:00 PM
- Savara to Present at the Citizens JMP Life Sciences Conference • Business Wire • 05/07/2024 08:05:00 PM
- Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 • Business Wire • 04/08/2024 12:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM